PracticeUpdate Oncology May 2019

PROVEN EFFICACY THAT REDEFINES FIRST LINE 1,2 KISQALI is a CDK4/6 inhibitor used in combination with an aromatase inhibitor for FIRST-LINE HR+/HER2- advanced/metastatic breast cancer 1

THE FIRST PBS LISTED CDK4/6 INHIBITOR

BEFORE PRESCRIBING, PLEASE REVIEW PBS AND PRODUCT INFORMATION AVAILABLE IN THE PRIMARY ADVERTISEMENT OF THIS PUBLICATION.

ABBREVIATIONS: CDK, cyclin dependent kinase; HR+, hormone receptor positive; HER-, human epidermal growth factor receptor negative. REFERENCES: 1. KISQALI Product Information. 2. Hortobagyi GN et al. Ann Oncol 2018;29:1541-7.

Novartis Pharmaceuticals Australia Pty Limited ABN 18 004 244 160. 54 Waterloo Road, Macquarie Park NSW 2113. Ph (02) 9805 3555. ® Registered Trademark. Item No: AU-8895. Date of preparation: April 2019. 3291RC_PUO_FP.